Alliance for Pandemic Preparedness

May 27, 2021

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

Category:

Topic:

Keywords (Tags):

  • The efficacy in preventing symptomatic COVID-19 14 days after the second dose for two inactivated SARS-CoV-2 vaccines (derived from strains WIV04 and HB02) was 73% (95% CI, 58%-82%) and 78% (95% CI, 65%-86%), respectively, in an interim analysis of a randomized, placebo-controlled phase 3 trial among adults aged ≥18 years without known prior infection in the United Arab Emirates and Bahrain (n=38,206). During a median follow-up of 77 days, symptomatic COVID-19 was identified in 26 participants in the WIV04 group (n=12,743), 21 in the HB02 group (n=12,726), and 95 in the control group (n=12,737). The country of origin of the participants included the UAE (24%), India (14%), Bangladesh (10%), China (10%), Pakistan (9%), Bahrain (7%), Egypt (5%), the Philippines (4%), Nepal (2%), and Syria (2%). Adverse reactions 7 days after each dose occurred in 42%-47% of participants, while serious adverse events occurred in ≤0.6% in all 3 groups.

Al Kaabi et al. (May 26, 2021). Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. JAMA. https://doi.org/10.1001/jama.2021.8565